CD79A and cancer: Initial ADCC experiments with bispecific IgG1-antibodies where one of the F (ab’)2 fragments was directed at the FcαR receptor and the other to a target antigen highlighted the potential use of IgA antibodies in the context of malignancies (Valerius et al., 1997).